Seminars in Hematology
Volume 43, Issue 4 , Pages 213-220, October 2006

Standard Treatment of Advanced-Stage Diffuse Large B-Cell Lymphoma

  • Bertrand Coiffier

      Affiliations

    • Corresponding Author InformationAddress correspondence to Professor Bertrand Coiffier, MD, Hematology Department, CH Lyon-Sud, 69495 Pierre Benite, France.

Hospices Civils de Lyon and Université Claude Bernard, Lyon, France.

Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoma and is not localized in 70% of the cases. Even if the clinical picture, the morphologic aspect, and the prognostic parameters are different from one patient to another, the standard treatment is the same for all patients. Currently, treatment decision is based on the International Prognostic Index (IPI) and age of the patient. Outcome has been completely modified with the introduction of rituximab in combination with chemotherapy. A review of standard treatment and remaining questions is presented.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0037-1963(06)00152-1

doi:10.1053/j.seminhematol.2006.07.004

Seminars in Hematology
Volume 43, Issue 4 , Pages 213-220, October 2006

Article Tools

* Image Usage & Resolution